Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chang Kang Granules for Diarrhea-predominant Irritable Bowel Syndrome
CTR20200075Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of changkang granules in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Jan 2020; status: completed.
02
Drugs
changkang granules
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on CTR20200075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200075.